From HTS to Market: the Discovery and Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIV - Accounts in Drug Discovery Case Studies in Medicinal Chemistry - page 189

Figure 9.3 Correlations between antiviral activity [IC 90 (nM)] and (top) MIP-1b
binding and (bottom) a cell fusion-based assay.
improved correlation with the fusion assay, and a greater dynamic range with
which antiviral activity can be predicted. Throughout this chapter we will refer
to these assays as binding, fusion or antiviral (AV).
9.6 Developing SAR
Before embarking on the production of a wide range of analogues to follow 1,a
broader activity profile was determined to identify key off-target activities that